NO176466C - Fremgangsmåte til fremstilling av doseringsenhet for avgivelse av et aktivt middel til et bruksmiljö - Google Patents

Fremgangsmåte til fremstilling av doseringsenhet for avgivelse av et aktivt middel til et bruksmiljö

Info

Publication number
NO176466C
NO176466C NO884259A NO884259A NO176466C NO 176466 C NO176466 C NO 176466C NO 884259 A NO884259 A NO 884259A NO 884259 A NO884259 A NO 884259A NO 176466 C NO176466 C NO 176466C
Authority
NO
Norway
Prior art keywords
delivery
preparation
active agent
dosage unit
use environment
Prior art date
Application number
NO884259A
Other languages
English (en)
Norwegian (no)
Other versions
NO884259L (no
NO176466B (no
NO884259D0 (no
Inventor
Atul Davdatt Ayer
David R Swanson
Anthony L Kuczynski
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO884259D0 publication Critical patent/NO884259D0/no
Publication of NO884259L publication Critical patent/NO884259L/no
Publication of NO176466B publication Critical patent/NO176466B/no
Publication of NO176466C publication Critical patent/NO176466C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO884259A 1987-10-02 1988-09-27 Fremgangsmåte til fremstilling av doseringsenhet for avgivelse av et aktivt middel til et bruksmiljö NO176466C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (4)

Publication Number Publication Date
NO884259D0 NO884259D0 (no) 1988-09-27
NO884259L NO884259L (no) 1989-04-03
NO176466B NO176466B (no) 1995-01-02
NO176466C true NO176466C (no) 1995-04-12

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
NO884259A NO176466C (no) 1987-10-02 1988-09-27 Fremgangsmåte til fremstilling av doseringsenhet for avgivelse av et aktivt middel til et bruksmiljö

Country Status (22)

Country Link
US (1) US4816263A (fr)
JP (1) JP2590235B2 (fr)
KR (1) KR950010151B1 (fr)
AT (1) AT402689B (fr)
AU (1) AU615215B2 (fr)
BE (1) BE1001101A5 (fr)
CA (1) CA1317550C (fr)
CH (1) CH677609A5 (fr)
DE (1) DE3833282C2 (fr)
DK (1) DK175564B1 (fr)
ES (1) ES2011120A6 (fr)
FI (1) FI92554C (fr)
FR (1) FR2622798B1 (fr)
GB (1) GB2210266B (fr)
IE (1) IE61862B1 (fr)
IT (1) IT1234215B (fr)
LU (1) LU87351A1 (fr)
NL (1) NL194748C (fr)
NO (1) NO176466C (fr)
PT (1) PT88618B (fr)
SE (1) SE503471C2 (fr)
ZA (1) ZA887362B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
WO2002100344A2 (fr) * 2001-06-11 2002-12-19 Xenoport, Inc. Conjugues d'amino acides permettant d'obtenir des concentrations systemiques soutenues d'analogues du gaba
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2004053192A1 (fr) * 2002-12-11 2004-06-24 Xenoport, Inc. Formes posologiques administrees oralement de promedicaments analogues de gaba fondu a toxicite reduite
EP1608357A4 (fr) * 2003-03-31 2008-03-26 Xenoport Inc Traitement ou prevention des bouffees de chaleur par utilisation de promedicaments a base d'analogues des gaba
PT1660440E (pt) * 2003-08-20 2012-05-15 Xenoport Inc Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização
EP2354120A1 (fr) 2003-08-20 2011-08-10 XenoPort, Inc. Synthèse de promédicaments a base de carbamate d'acyloxyalkyle et leurs intermédiaires
NZ545884A (en) * 2003-09-11 2010-01-29 Xenoport Inc Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
NZ545989A (en) * 2003-09-17 2009-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
WO2006050471A2 (fr) * 2004-11-03 2006-05-11 Xenoport, Inc. Prodrogues d'acyloxyalkyl carbamate de l'acide 3-aminopropylsulfinique, et procedes de synthese et d'utilisation
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
ATE469880T1 (de) 2005-06-20 2010-06-15 Xenoport Inc Acyloxyalkylcarbamat-prodrugs von tranexansäure und anwendung
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
WO2007027476A2 (fr) * 2005-08-26 2007-03-08 Xenoport, Inc. Traitement de l'ejaculation prematuree utilisant des prodrogues de gabapentine et de pregabaline
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
ES2456674T3 (es) 2006-05-26 2014-04-23 Signature Therapeutics, Inc. Liberación controlada de opioides fenólicos
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CN101652133A (zh) * 2006-12-08 2010-02-17 克塞诺波特公司 Gaba类似物的前药用于治疗疾病的用途
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
WO2008124121A1 (fr) * 2007-04-06 2008-10-16 Scidose, Llc Polythérapie associant des statines et des 1,4-dihydropyridine-3,5-dicarboxydiesters et combinaisons de ceux-ci
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
EP2621282B1 (fr) 2010-09-28 2020-04-15 The Regents of The University of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
AU2018234911B2 (en) 2017-03-17 2024-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
DK175564B1 (da) 2004-12-06
SE8803486L (sv) 1989-04-03
KR950010151B1 (ko) 1995-09-11
NO884259L (no) 1989-04-03
ATA242288A (de) 1996-12-15
PT88618B (pt) 1993-07-30
LU87351A1 (fr) 1989-04-06
JPH01113316A (ja) 1989-05-02
FR2622798A1 (fr) 1989-05-12
FR2622798B1 (fr) 1993-10-15
JP2590235B2 (ja) 1997-03-12
ZA887362B (en) 1989-06-28
PT88618A (pt) 1989-07-31
CH677609A5 (fr) 1991-06-14
SE8803486D0 (sv) 1988-09-30
IT1234215B (it) 1992-05-06
DK545088D0 (da) 1988-09-29
FI884526A (fi) 1989-04-03
DE3833282C2 (de) 1997-02-13
AU2293888A (en) 1989-04-06
NL194748B (nl) 2002-10-01
AU615215B2 (en) 1991-09-26
BE1001101A5 (fr) 1989-07-11
IE61862B1 (en) 1994-11-30
GB2210266A (en) 1989-06-07
NO176466B (no) 1995-01-02
FI92554C (fi) 1994-12-12
DK545088A (da) 1989-04-03
GB8822852D0 (en) 1988-11-02
CA1317550C (fr) 1993-05-11
AT402689B (de) 1997-07-25
KR890006218A (ko) 1989-06-12
IE882960L (en) 1989-04-02
NL8802401A (nl) 1989-05-01
NO884259D0 (no) 1988-09-27
DE3833282A1 (de) 1989-04-20
IT8867880A0 (it) 1988-09-30
NL194748C (nl) 2003-02-04
FI884526A0 (fi) 1988-09-30
ES2011120A6 (es) 1989-12-16
FI92554B (fi) 1994-08-31
SE503471C2 (sv) 1996-06-24
US4816263A (en) 1989-03-28
GB2210266B (en) 1991-07-24

Similar Documents

Publication Publication Date Title
NO176466C (no) Fremgangsmåte til fremstilling av doseringsenhet for avgivelse av et aktivt middel til et bruksmiljö
NO176902C (no) Fremgangsmåte for fremstilling av en doseringsenhet for avgivelse av et aktivt middel
NL193308B (nl) Doseervorm geschikt voor de afgifte van een preparaat van een heilzaam middel aan een gebruiksomgeving.
NO883667L (no) Kapsel for farmasoeytisk virksomme innholdsstoffer av en droge.
DK583789A (da) System til transmucosal indgivelse af den aktive bestanddel af et laegemiddel
IT8567263A0 (it) Dispositivo di erogazione per la somministrazione controllata di un agente benefico particolamente di un farmaco a ruminanti
DK82982A (da) Bandage til indgift af et gavnligt laegemiddel
IT8667657A0 (it) Nante dispositivo erogatore per la sommi nistrazione di un agente benefico all ambiente d uso particolarmente per la somministrazione di un agente terapeutico ad un animale rumi
FI884384A0 (fi) Yliannostuksen estolla varustettu sumutinpakkaus fysiologisesti aktiivisten aineiden itseannostelemiseksi
GR80494B (en) Intra-pocket drug delivery devices for treatment of periodontal diseases
FI831998L (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva pyrazinonderivat
NO843084L (no) Fremgangsmaate for fremstilling av terapeutisk aktive adenosin-derivater
NZ196288A (en) Pharmaceutical active substance administration
NO883500D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk aktivt nitrometan.
IT8448983A0 (it) Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
DE2965732D1 (en) Pharmaceutical composition comprising a water soluble salt of amoxycillin and polyvinylpyrrolidone, and a vial containing a unit dose of said composition
NO820112L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater
IT1223343B (it) Formulazioni farmaceutiche per somministrazione transdermica
IT8468196A0 (it) Dispositivo osmotico e procedimento per l erogazione di un agente benefico particolarmente di un farmaco ad un ambiente d uso
BR8009059A (pt) Administracao de substancia medicas ativas
DK298389D0 (da) Farmaceutisk praeparat til topisk anvendelse omfattende et amin-funktionelt medikament
NO170012C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzamider
HUT51854A (en) Insecticides containing as active substance derivatives of chrisanthemate
NO862321D0 (no) Fysiologisk middel for oekning av transdermal avlevering av legemidler.
PT87079A (pt) Process for the preparation of dopamine-beta-hydroxylase inhibitors and of pharmaceutical compounds containing them

Legal Events

Date Code Title Description
MK1K Patent expired